Immune Tolerance Network (UM1 Clinical Trial Required)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 24, 2026
- Closes
- Jan 29, 2027 (in 100 days)
Classification and identifiers
- Solicitation number
- RFA-AI-28-005
- Assistance listing (CFDA)
- 93.855
Amount
Amount not listed here. Check the official program.
Who can apply
Public colleges and universities and Local government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the continued support of the Collaborative Network for Clinical Research on Immune Tolerance. The purpose of this program is to enhance understanding of the underlying mechanisms of the induction, maintenance, and loss of immune tolerance in humans; and to develop improved tolerogenic interventions for the prevention and treatment of immune system mediated diseases (including transplant rejection, autoimmune diseases, and asthma and allergic diseases). The three major scientific goals include: 1) conduct clinical trials to determine the safety and efficacy of promising tolerogenic strategies in liver, kidney and pancreatic islet transplantation; allergic diseases and asthma; and autoimmun...